Nebivolol hydrochloride is a beta-blocker used primarily for managing hypertension and chronic heart failure. It is known for its selective beta-1 adrenergic blocking activity and its ability to improve endothelial function due to its nitric oxide-mediated vasodilatory effects.
Nebivolol hydrochloride is prescribed for:
| Brand Name | Cardoneb |
|---|---|
| Type | Tablet |
| Weight | 5 mg |
| Generic | Nebivolol Hydrochloride |
| Manufacturer | Eskayef Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Nebivolol hydrochloride works by:
Effects on blood pressure are typically observed within 1-2 hours of administration, with peak effects occurring around 4-6 hours. The full therapeutic effect for heart failure may take several weeks to become evident.
Nebivolol hydrochloride is well-absorbed orally, with peak plasma concentrations reached within 1-2 hours. The bioavailability of nebivolol is approximately 12% due to first-pass metabolism in the liver.
Nebivolol is primarily metabolized in the liver through the cytochrome P450 system (CYP2D6), with a significant amount excreted in the urine as metabolites. Only a small fraction is excreted unchanged in the urine.
The usual dosage for adults is:
Take nebivolol hydrochloride orally with or without food. Swallow tablets whole; do not chew or crush. Consistency in dosing time and adherence to the prescribed dosage is essential for optimal effectiveness.
Common side effects may include:
Overdose or toxicity may lead to severe bradycardia, hypotension, or heart failure exacerbation. Symptoms of overdose can include severe dizziness, fainting, or worsening heart failure. Seek medical attention immediately in case of overdose.
Precautions include:
Nebivolol may interact with:
Use with caution in patients with:
Significant drug interactions may include:
Food interactions are minimal, but taking nebivolol with or without food consistently can help maintain stable drug levels. Avoid excessive alcohol intake as it may enhance hypotensive effects.
Consult a healthcare provider before use during pregnancy. Nebivolol should be used only if the potential benefit justifies the risk to the fetus, as beta-blockers may affect fetal growth and development.
Consult a healthcare provider before use during lactation. Nebivolol may pass into breast milk, so the risks and benefits should be evaluated before starting treatment.
In case of acute overdose, symptoms may include severe bradycardia, hypotension, dizziness, and worsening heart failure. Seek immediate medical attention and provide supportive care as needed.
Contraindications include:
For effective use:
Store nebivolol hydrochloride in a cool, dry place at room temperature (15-30°C or 59-86°F). Keep the container tightly closed and out of reach of children. Avoid exposure to moisture and direct sunlight.
The volume of distribution for nebivolol is approximately 3.3 to 4.8 L/kg. This indicates the drug is distributed throughout the body, particularly in cardiac tissues where it exerts its therapeutic effects.
The elimination half-life of nebivolol is approximately 10 to 12 hours, which supports once-daily dosing and allows for stable blood levels throughout the day.
Nebivolol is primarily cleared through the liver with a significant amount excreted in the urine. The clearance rate is influenced by hepatic function and genetic variability in CYP2D6 enzyme activity.
See in details version Cardoneb Tablet 5 mg also Cardoneb Tablet 5 mg in bangla